Athersys' (ATHX) MultiStem Cell Therapy Succeeds In Study
Zacks Investment Research | Jan 24, 2019 02:20AM ET
Shares of Athersys, Inc. ( (NASDAQ:ATHX) went up about 14% after the company announced positive results from its exploratory clinical study on the intravenous administration of MultiStem cell therapy to treat patients suffering from acute respiratory distress syndrome (ARDS).
The exploratory study evaluated the impact of MultiStem treatment in subjects with acute onset of moderate to severe ARDS. The study demonstrated lower mortality of 25% in the MultiStem treatment group versus 40% in the placebo group.
The results also showed that patients in the MultiStem treatment group experienced 40.2% higher ventilator-free (VF (NYSE:VFC)) days compared to those in the placebo group. The patients in the MultiStem treatment group also had 27.2% higher ICU-free days compared to those in the placebo group.
Patients enrolled in the study were evaluated through 28 days for the primary clinical assessment and will be further assessed through a one-year follow-up period. MultiStem cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways. Per Athersys, the exploratory study met all of its key objectives, and the company believes that the therapy can be administered in another critical care area where there is substantial unmet medical need.
Share price of Athersys has decreased 14.9% in the past year compared with the industry ’s decline of 22.8%.
In addition to this ARDS study, Athersys is conducting ongoing studies in ischemic stroke (MASTERS-2 phase III study) and acute myocardial infarction. The company is planning to initiate a study to treat severe trauma patients. Athersys is also supporting studies in Japan conducted by its partner Healios K.K, targeting ischemic stroke (TREASURE study) and ARDS.
Zacks Rank & Stocks to Consider
Athersys currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks worth considering are Celgene Corp. (NASDAQ:CELG) , Aduro Biotech, Inc. (NASDAQ:ADRO) and Axovant Sciences Ltd. (NASDAQ:AXON) . All the companies sport a Zacks Rank #1 (Strong Buy). You can see .
Celgene’s earnings per share estimates have increased from $8.79 to $8.80 for 2018 in the past 90 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 2.54%.
Get The News You Want
Aduro’s loss per share estimates have narrowed from $1.11 to $1.06 for 2018 in the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 5.49%.
Axovant’s loss per share estimates have narrowed from $1.60 to $1.25 for 2019 and from $1.35 to $1.03 for 2020 in the past 90 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.